RAG1 and cancer: Interestingly, we found that BNT162b2 had a similar anti-cancer effect in the μMT mouse model in comparison to that in WT mice, however, it had no obvious therapeutic effects in Rag1−/− mice, indicating that the BNT162b2-based cancer therapy was predominantly T cell-dependent.